On September 15, the U.S. Food and Drug Administration announced a new set of actions under its Operation TrialBlazer initiative, and at the center sits the Expedited Investigational New Drug (IND) Pilot Program — a pathway designed, as the agency frames it, to accelerate first-in-human clinical trials without loosening the safety oversight that patients depend on. For those of us running early-phase work, there is a particular quiet tension in moments like this, when the procedural rails beneath our protocols quietly shift.
A New Lane for First-in-Human Studies
The pilot introduces a structural change worth pausing on. Under the program, drug sponsors can partner with qualified research institutions and submit IND components on a rolling basis rather than as a single bundled package. For our colleagues shepherding early-phase oncology and rare-disease programs, that means the conversation about what the FDA needs to see can begin before the entire dossier is polished — a meaningful shift in workload, in cycle time, and in how quickly a molecule reaches its first participant. The agency emphasizes that safety oversight remains intact; the change is procedural, not permissive, and the lived experience of the participant on day one of dosing is meant to look the same as it did last quarter.
A Sobering Signal From the Post-Market World
Speed into the clinic, though, is only half of the story we owe our patients. A study published in JAMA Neurology, led by researchers from the University of Liverpool and the University of Zurich, reminds us how much vigilance work continues long after a label is set. Analyzing anonymized records from 165 healthcare organizations within the international TriNetX network — more than 2.29 million adults with epilepsy, narrowed to 9,529 who started an antiseizure medication while taking a direct oral anticoagulant (DOAC) — the team found that patients on levetiracetam alongside a DOAC faced nearly twice the risk of stroke, heart attack, or other serious thromboembolic events compared with those on alternative antiseizure medications. The mortality signal was equally sobering: a 60% higher risk of death, with no significant difference in major bleeding.
Levetiracetam was the antiseizure medication taken by 57% of the study population. It has long been favored in patients who also need anticoagulation precisely because clinicians believed it interacted less with these blood thinners. As Dr. Gashirai Mbizvo, Senior Clinical Lecturer in Neurology at the University of Liverpool and Consultant Neurologist at The Walton Centre NHS Foundation Trust, put it: "Levetiracetam is often favoured in people taking anticoagulants because it has generally been assumed not to interact significantly with these medications. Our findings challenge that assumption and suggest that patients taking levetiracetam alongside direct oral anticoagulants may face a substantially higher risk of serious blood clots and death than those taking alternative antiseizure medications." He was careful to add that the work identifies a safety signal rather than proof of causation, and urged patients not to change either therapy without medical advice. Older enzyme-inducing agents like carbamazepine and phenytoin carried their own familiar pattern — a 55% higher risk of blood clots paired with a 38% lower risk of major bleeding — consistent with reduced anticoagulant effectiveness.
What Speed Owes to Vigilance
When we sit with these two pieces of news side by side, the through-line is unmistakable. Faster first-in-human pathways raise the value of everything that comes after them — the registries, the electronic-health-record networks, the pragmatic collaborations like the TriNetX analysis above. Our industry's promise to a participant entering a Phase 1 unit is not only that the trial is well-designed; it is that someone will still be watching, years later, when the prescribing decisions move from a research protocol into a daily care pathway. As Professor Marian Galovic of the University of Zurich noted, "This study demonstrates the value of international collaboration in addressing important questions that cannot easily be answered through conventional clinical trials." We would only add that the collaboration cannot end when the approval letter arrives.